Symbiotec Pharmalab IPO Day 4 Final Subscription Status: 75.08x Subscribed; GMP at ₹287
The Symbiotec Pharmalab IPO Day 4 final subscription closed at 75.08 times on 27 August 2026, with Qualified Institutional Buyers (QIBs) leading at 181.20x. Non-Institutional Investors (NIIs) subscribed 77.56x, retail investors 13.69x, and employees 16.32x. The IPO is now closed. The latest available Grey Market Premium (GMP) was around ₹287, indicating a softer grey-market signal despite the sharp final-day bidding surge.
| Metric | Final update |
| Bidding day | Day 4, final |
| Data status | Final after bidding closed on 27 August 2026 |
| Overall subscription | 75.08x |
| QIB subscription | 181.20x |
| NII subscription | 77.56x |
| Retail subscription | 13.69x |
| Employee subscription | 16.32x |
| Current GMP | Around ₹287 |
| GMP percentage | About 29.0% |
| Indicative price | ₹1,275 |
| Closing date | 27 August 2026 |
Symbiotec Pharmalab IPO Day 4 Final Subscription Status
The Day 4 final subscription data shows a major late increase in institutional demand. QIBs became the most subscribed category at 181.20x, overtaking NIIs, which closed at 77.56x.
| Investor category | Day 4 final subscription |
| Qualified Institutional Buyers (QIBs) | 181.20x |
| Non-Institutional Investors (NIIs) | 77.56x |
| Retail Individual Investors | 13.69x |
| Employees | 16.32x |
| Overall | 75.08x |
The QIB portion recorded the highest final multiple, while NII demand also remained substantially above the overall levels seen earlier in the bidding period. Retail and employee categories were comfortably oversubscribed but finished at much lower multiples than QIBs and NIIs.
Subscription multiples reflect shares bid for relative to shares available in each reserved category. They do not represent the number of unique applicants, and comparisons should account for differences in category allocation.
Final Day-wise Subscription Trend
The IPO’s bidding pattern changed sharply on the closing day.
| Bidding stage | Overall subscription | Main development |
| Day 1 close | 0.80x | Issue remained below full subscription |
| Day 2 close | 1.95x | Overall book crossed 1x |
| Day 3 close | 5.62x | NII and retail demand accelerated |
| Day 4 final subscription | 75.08x | QIB demand surged to 181.20x |
The move from 5.62x at the Day 3 close to 75.08x in the Day 4 final subscription was driven primarily by institutional bidding. QIB subscription rose from below 1x on Day 3 to 181.20x at the final close.
This means the final result was much broader than the demand pattern visible earlier in the issue, although QIB and NII bidding contributed disproportionately to the final multiple.
Symbiotec Pharmalab IPO GMP Today and Estimated Listing Price
The latest available Symbiotec Pharmalab IPO GMP was around ₹287 per share during the afternoon of 27 August 2026.
At the ₹988 upper price band:
Indicative price = ₹988 + ₹287 = ₹1,275
GMP percentage = ₹287 ÷ ₹988 × 100 = about 29.0%
The ₹287 reading was below an available ₹340 reading on 26 August, representing a decline of ₹53. Another current tracker also showed a reading in the mid-₹280 range, indicating reasonable agreement around the latest level.
GMP is unofficial, unregulated, and can change quickly. It is not published by SEBI, NSE, or BSE. The ₹1,275 figure is only an indicative calculation and does not guarantee the listing price or listing gains.
What Stands Out in Today’s Bidding
The clearest signal from the Day 4 final subscription is the late institutional build-up. QIB demand finished at 181.20x after remaining below full subscription through much of the earlier bidding period. NII demand also closed at a high of 77.56x.
At the same time, the GMP moved lower even as formal bidding accelerated sharply. This subscription-GMP divergence is important because the two indicators measure different things. Subscription captures bids submitted through the formal IPO process, while GMP reflects unofficial grey-market sentiment.
The final subscription numbers do not establish fair valuation, business quality, or future returns, and the GMP does not guarantee listing performance.
IPO Details Retail Investors Need
| IPO detail | Information |
| Price band | ₹938 to ₹988 per share |
| Lot size | 15 shares |
| Minimum retail investment | ₹14,820 at upper band |
| Issue size | About ₹1,757 crore |
| Fresh issue | ₹150 crore |
| Offer for Sale (OFS) | About ₹1,607 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 27 August 2026 |
| Expected allotment date | 28 August 2026 |
| Expected listing date | 1 September 2026 |
| Exchange | NSE and BSE |
Most of the issue consists of an Offer for Sale (OFS), so proceeds from that portion go to the selling shareholders rather than to the company.
Brief Company and Financial Context
Symbiotec Pharmalab develops and manufactures Active Pharmaceutical Ingredients (APIs), biotechnology products, and complex injectables, with a significant position in corticosteroid and steroidal-hormone APIs.
Revenue from operations increased from ₹751.55 crore in FY2025 to ₹869.15 crore in FY2026. Separately, total income, which includes other income in addition to operating revenue, rose from ₹755.98 crore to ₹872.26 crore. Profit After Tax (PAT) increased from ₹96.79 crore to ₹109.90 crore.
The company intends to use about ₹112.5 crore from the fresh issue to repay or prepay certain borrowings. Product concentration, regulatory compliance, and valuation at the upper price band remain material considerations.
What Happens Next
With the Day 4 final subscription complete, the next scheduled step is the basis of allotment, expected on 28 August 2026. Refund or fund-unblocking and demat-credit processes are expected to follow before the shares are scheduled to list on NSE and BSE on 1 September 2026.
Frequently Asked Questions (FAQs)
Q: What was the Symbiotec Pharmalab IPO Day 4 final subscription?
A: The Symbiotec Pharmalab IPO Day 4 final subscription closed at 75.08x overall on 27 August 2026. QIBs led at 181.20x, followed by NIIs at 77.56x, employees at 16.32x, and retail investors at 13.69x.
Q: Which category led the Symbiotec Pharmalab IPO Day 4 final subscription?
A: Qualified Institutional Buyers led the final bidding with a subscription of 181.20x. The NII category was subscribed 77.56x, while retail and employee portions closed at 13.69x and 16.32x, respectively.
Q: What is the Symbiotec Pharmalab IPO GMP today?
A: The latest available Grey Market Premium was around ₹287 per share during the afternoon of 27 August 2026. This was below an available ₹340 reading from the previous day, showing that GMP softened despite the sharp final subscription increase.
Q: What listing price does the current Symbiotec Pharmalab IPO GMP indicate?
A: Adding the ₹287 GMP to the ₹988 upper price band gives an indicative price of about ₹1,275 per share. That represents a GMP of roughly 29.0%, but the actual listing price can differ materially.
Q: Does the 75.08x Day 4 final subscription guarantee a premium listing?
A: No. A high final subscription multiple shows strong bidding relative to the shares available, but it does not guarantee a premium listing, fair valuation, business quality, or future returns. GMP is also unofficial and does not provide a listing-price guarantee.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
